Myosin

Curi Bio Launches MantaReady™ iPSC-Derived Skeletal Muscle Myoblasts

Retrieved on: 
Tuesday, June 6, 2023

Curi Bio , a leading developer of human stem cell-based platforms for drug discovery, today announced the commercial launch of their MantaReadyTM iPSC-Derived Skeletal Muscle Myoblasts specifically optimized for creating human 3D engineered muscle tissues for preclinical therapeutic discovery, high-throughput screening, and disease modeling.

Key Points: 
  • Curi Bio , a leading developer of human stem cell-based platforms for drug discovery, today announced the commercial launch of their MantaReadyTM iPSC-Derived Skeletal Muscle Myoblasts specifically optimized for creating human 3D engineered muscle tissues for preclinical therapeutic discovery, high-throughput screening, and disease modeling.
  • View the full release here: https://www.businesswire.com/news/home/20230606005566/en/
    Curi Bio Launches MantaReady™ 3D Skeletal Muscle Myoblasts – Ready to Cast Isogenic Control and Duchenne Muscular Dystrophy Human Myoblasts for 3D Engineered Muscle Tissue (Photo: Business Wire)
    The myoblast lines were developed in response to the growing demand for high quality iPSC-derived cells required for 3D skeletal muscle engineering.
  • “Through our innovative technology, we’re able to provide researchers with high-quality skeletal muscle cells that can be used to accelerate the drug discovery process and translational muscle biology research,“ said Curi Bio CEO Nick Geisse.
  • To learn more about how MantaReady iPSC-derived skeletal muscle cells can improve the predictive power of your experiments, or about Curi Bio’s other human-relevant preclinical platform technologies and services, please reach out at www.curibio.com/contact .

Global Hypertrophic Cardiomyopathy Pipeline Market Insight Report 2022 Featuring Key Players in this Space - Novartis, Imbria Pharmaceuticals, Cytokinetics, & MyoKardia - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 25, 2022

This "Hypertrophic Cardiomyopathy- Pipeline Insight, 2022" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Hypertrophic Cardiomyopathy pipeline landscape.

Key Points: 
  • This "Hypertrophic Cardiomyopathy- Pipeline Insight, 2022" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Hypertrophic Cardiomyopathy pipeline landscape.
  • A detailed picture of the Hypertrophic Cardiomyopathy pipeline landscape is provided which includes the disease overview and Hypertrophic Cardiomyopathy treatment guidelines.
  • The assessment part of the report embraces, in depth Hypertrophic Cardiomyopathy commercial assessment and clinical assessment of the pipeline products under development.
  • It also analyses Hypertrophic Cardiomyopathy therapeutic drugs key players involved in developing key drugs.

INTRODUCING INTANDEM: A MENTORSHIP-BASED GROWTH MARKETING PROGRAM FOR MINORITY-FOUNDED STARTUPS

Retrieved on: 
Tuesday, March 8, 2022

The InTandem Program features a proprietary curriculum and actionable growth marketing roadmap to help prime minority-founded startups for accelerated growth as they scale post-series A funding.

Key Points: 
  • The InTandem Program features a proprietary curriculum and actionable growth marketing roadmap to help prime minority-founded startups for accelerated growth as they scale post-series A funding.
  • "Through strategic partnerships, we are able to lend technology-based growth marketing expertise and mentorship to help level the playing field for this important community."
  • InTandem, in partnership with Google, is a complimentary mentorship-based growth marketing program for startups with founders from underrepresented communities.
  • The InTandem program features a proprietary curriculum and actionable growth marketing roadmap to help prime minority-founded startups for accelerated growth as they scale post-series A funding.

Cytokinetics to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, June 2, 2021

Cytokinetics is also developing CK-274, a next-generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM).

Key Points: 
  • Cytokinetics is also developing CK-274, a next-generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM).
  • Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements.
  • Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics product candidates.
  • Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release.

Bristol Myers Squibb Presents Late-Breaking Phase 3 Data Demonstrating Health Status Benefits of Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy at American College of Cardiology’s 70th Annual Scientific Session

Retrieved on: 
Saturday, May 15, 2021

At 30 weeks, the change in Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ OSS) was greater in mavacamten patients than placebo, with similar benefits across all KCCQ subscales.

Key Points: 
  • At 30 weeks, the change in Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ OSS) was greater in mavacamten patients than placebo, with similar benefits across all KCCQ subscales.
  • Moreover, a greater proportion of mavacamten patients achieved a very large, clinically meaningful improvement (\xe2\x89\xa520 points) in the KCCQ OSS, compared to placebo, 36% [33/92] vs. 15% [13/88].
  • A change of at least 5 points is required to be considered clinically significant.
  • Mavacamten reduces cardiac muscle contractility by inhibiting excessive myosin-actin cross-bridge formation that results in hypercontractility, left ventricular hypertrophy and reduced compliance.

Cytokinetics Announces Three Upcoming Presentations Related to Heart Failure and Hypertrophic Cardiomyopathy at American College of Cardiology 70th Annual Scientific Session

Retrieved on: 
Monday, May 10, 2021

b'SOUTH SAN FRANCISCO, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced three presentations at the American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21) taking place online from May 15, 2021 - May 17, 2021.

Key Points: 
  • b'SOUTH SAN FRANCISCO, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced three presentations at the American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21) taking place online from May 15, 2021 - May 17, 2021.
  • Cytokinetics is also developing CK-274, a next-generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM).
  • Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act\'s Safe Harbor for forward-looking statements.
  • For further information regarding these and other risks related to Cytokinetics\' business, investors should consult Cytokinetics\' filings with the Securities and Exchange Commission.\n'

Cytokinetics to Hold Annual Meeting of Stockholders

Retrieved on: 
Wednesday, May 5, 2021

Immediately after the conclusion of the Annual Meeting of Stockholders, Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics\xe2\x80\x99 performance.\nDue to the COVID-19 pandemic, Cytokinetics will be taking certain precautionary measures to ensure the health and safety of those in attendance.

Key Points: 
  • Immediately after the conclusion of the Annual Meeting of Stockholders, Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics\xe2\x80\x99 performance.\nDue to the COVID-19 pandemic, Cytokinetics will be taking certain precautionary measures to ensure the health and safety of those in attendance.
  • Anyone exhibiting fever or flu-like symptoms will not be allowed entry to the building.\nStockholders of record at the close of business on March 22, 2021 are entitled to vote at Cytokinetics\xe2\x80\x99 Annual Meeting of Stockholders or to attend in person and submit questions to management.
  • Cytokinetics is also developing CK-274, a next-generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM).
  • Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release.

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Retrieved on: 
Tuesday, December 1, 2020

The grant was previously approved by the Compensation and Talent Committee of Cytokinetics Board of Directors under the companys Amended and Restated 2004 Equity Incentive Plan.

Key Points: 
  • The grant was previously approved by the Compensation and Talent Committee of Cytokinetics Board of Directors under the companys Amended and Restated 2004 Equity Incentive Plan.
  • Cytokinetics is also developing CK-274, a next- generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM).
  • Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics product candidates.
  • Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release.

Cytokinetics Announces Licensing Collaboration and Royalty Monetization Deals with RTW Investments Focused to CK-3773274, Next-Generation Cardiac Myosin Inhibitor

Retrieved on: 
Tuesday, July 14, 2020

As a differentiated, next-generation cardiac myosin inhibitor, CK-274 holds promise as an innovative treatment for hypercontractility that underlies hypertrophic cardiomyopathies and other indications, said Roderick T. Wong, MD, Managing Partner, RTW Investments, LP.

Key Points: 
  • As a differentiated, next-generation cardiac myosin inhibitor, CK-274 holds promise as an innovative treatment for hypercontractility that underlies hypertrophic cardiomyopathies and other indications, said Roderick T. Wong, MD, Managing Partner, RTW Investments, LP.
  • We are pleased to partner with Cytokinetics in China as well as to invest in upside that CK-274 may provide globally.
  • Under a separate funding agreement, Cytokinetics receives options for additional funding from RTW for the further development of CK-274 in HCMs.
  • CK-274 is a novel, oral, small molecule cardiac myosin inhibitor that company scientists discovered independent of its collaborations.

Cytokinetics Announces Baseline Characteristics from GALACTIC-HF at ACC.20/WCC Virtual

Retrieved on: 
Monday, March 30, 2020

Omecamtiv mecarbil is a novel investigational selective cardiac myosin activator that binds to the catalytic domain of myosin.

Key Points: 
  • Omecamtiv mecarbil is a novel investigational selective cardiac myosin activator that binds to the catalytic domain of myosin.
  • Omecamtiv mecarbil is being developed by Amgen in collaboration with Cytokinetics, with funding and strategic support from Servier.
  • Amgen holds an exclusive, worldwide license to omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization rights.
  • For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.